Long-term drug treatment in multiple sclerosis: safety success and concerns-Reference-Cited by-同舟云学术

Long-term drug treatment in multiple sclerosis: safety success and concerns

Published:2020-08-13 Issue:9 Volume:19 Page:1121-1142
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Jakimovski Dejan¹^ORCID,Vaughn Caila B²,Eckert Svetlana²,Zivadinov Robert¹³^ORCID,Weinstock-Guttman Bianca²^ORCID

Affiliation:

1. Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA

2. Jacobs Comprehensive MS Treatment and Research Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences University at Buffalo, Buffalo, NY, USA

3. Translational Imaging Center at Clinical Translational Research Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Stat37$e University of New York, Buffalo, NY, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2020.1805430

Reference226 articles.

1. Multiple sclerosis

2. Long‐term evolution of multiple sclerosis disability in the treatment era

3. Epidemiology and treatment of multiple sclerosis in elderly populations

4. Interferon β for Multiple Sclerosis

5. Interferon- mechanisms of action in multiple sclerosis

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteomic signatures of physical, cognitive, and imaging outcomes in multiple sclerosis;Annals of Clinical and Translational Neurology;2024-01-17

2. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry;Journal of Neurology;2023-12-22

3. Association of Higher Mediterranean Diet Adherence With Lower Prevalence of Disability and Symptom Severity, Depression, Anxiety, Stress, Sleep Quality, Cognitive Impairment, and Physical Inactivity in Older Adults With Multiple Sclerosis;Journal of Geriatric Psychiatry and Neurology;2023-11-29

4. Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis;Expert Review of Neurotherapeutics;2023-10-16

5. Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies;CNS Drugs;2023-09-23